OPKO HEALTH, INC.OPKEarnings & Financial Report
OPKO Health, Inc. is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol "OPK".
Revenue
$183.6M
Gross Profit
$84.7M
Operating Profit
$-33.1M
Net Profit
$14.0M
Gross Margin
46.1%
Operating Margin
-18.0%
Net Margin
7.6%
YoY Growth
1.0%
EPS
$0.02
OPKO HEALTH, INC. Q4 FY2024 Financial Summary
OPKO HEALTH, INC. reported revenue of $183.6M (up 1.0% YoY) for Q4 FY2024, with a net profit of $14.0M (up 121.1% YoY) (7.6% margin). Cost of goods sold was $99.0M, operating expenses totaled $117.8M.
Key Financial Metrics
| Total Revenue | $183.6M |
|---|---|
| Net Profit | $14.0M |
| Gross Margin | 46.1% |
| Operating Margin | -18.0% |
| Report Period | Q4 FY2024 |
OPKO HEALTH, INC. Annual Revenue by Year
OPKO HEALTH, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $606.9M).
| Year | Annual Revenue |
|---|---|
| 2025 | $606.9M |
| 2024 | $713.1M |
| 2023 | $863.5M |
| 2022 | $1.0B |
OPKO HEALTH, INC. Quarterly Revenue & Net Profit History
OPKO HEALTH, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $148.5M | -19.2% | $-31.3M | -21.1% |
| Q3 FY2025 | $151.7M | -12.6% | $21.6M | 14.3% |
| Q2 FY2025 | $156.8M | -13.9% | $-148.4M | -94.7% |
| Q1 FY2025 | $150.0M | -13.7% | $-67.6M | -45.1% |
| Q4 FY2024 | $183.6M | +1.0% | $14.0M | 7.6% |
| Q3 FY2024 | $173.6M | -2.8% | $24.9M | 14.3% |
| Q2 FY2024 | $182.2M | -31.4% | $-10.3M | -5.7% |
| Q1 FY2024 | $173.7M | -26.9% | $-81.8M | -47.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $173.7M | $182.2M | $173.6M | $183.6M | $150.0M | $156.8M | $151.7M | $148.5M |
| YoY Growth | -26.9% | -31.4% | -2.8% | 1.0% | -13.7% | -13.9% | -12.6% | -19.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.97B | $1.98B | $2.26B | $2.20B | $2.13B | $1.97B | $2.00B | $1.93B |
| Liabilities | $721.2M | $584.6M | $852.7M | $834.8M | $816.7M | $676.1M | $690.0M | $664.0M |
| Equity | $1.25B | $1.40B | $1.40B | $1.37B | $1.31B | $1.30B | $1.31B | $1.27B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-35.6M | $-26.4M | $-77.1M | $-44.4M | $-34.6M | $-83.4M | $-34.6M | $-25.9M |